259180-69-3

Basic information

• Product Name: 2-CYANOMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2-CYANOMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER
• CAS NO: 259180-69-3
• Molecular Formula: C11H18N2O3
• Molecular Weight: 226.27
• Mol File: 259180-69-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 358.3±27.0 °C(Predicted)
• Appearance: /
• Density: 1.094±0.06 g/cm3(Predicted)
• PKA: -2.34±0.40(Predicted)
• CAS DataBase Reference: 2-CYANOMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CYANOMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(259180-69-3)
• EPA Substance Registry System: 2-CYANOMETHYL-MORPHOLINE-4-CARBOXYLIC ACID TERT-BUTYL ESTER(259180-69-3)

Safety Data

• Hazardous Substances Data: 259180-69-3(Hazardous Substances Data)

Usage

General Description

2-Cyanomethyl-morpholine-4-carboxylic acid tert-butyl ester, also known as CARBOXYLIC_ACID_T-BUTYL_ESTER, is a chemical compound. One of its distinguishing properties is its ability to catalyze reactions, this means it helps speed up the reaction without taking part in it chemically itself. Its molecular formula is C14H25N2O3, signifying that it is made up of 14 atoms of carbon (C), 25 of hydrogen (H), 2 of nitrogen (N), and 3 of oxygen (O). The structure of this compound lets it react in various ways with other elements.

Upstream product

• 130546-33-7 4-t-butoxycarbonyl-2-[(4-methylphenylsulphonyloxy)methyl]morpholine 
• 135065-69-9 tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate 
• 135065-76-8 tert-butyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate 
• 606139-90-6 tert-butyl (2S)-2-{[(methylsulfonyl)oxy]methyl}morpholine-4-carboxylate 
• 135065-71-3 (R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 
• 503455-76-3 (R)-tert-butyl 2-(((methylsulfonyl)oxy)methyl)morpholine-4-carboxylate 

Downstream Products

• 259180-78-4 (±)-tert-butyl 2-(2-aminoethyl)morpholine-4-carboxylate 

Relevant articles and documents

Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors

A number of reports have recently been published describing the discovery and optimization of bromo and extraterminal inhibitors which are selective for the second bromodomain (BD2); these include our own work toward GSK046 (3) and GSK620 (5). This paper describes our approach to mitigating the genotoxicity risk of GSK046 by replacement of the acetamide functionality with a heterocyclic ring. This was followed by a template-hopping and hybridization approach, guided by structure-based drug design, to incorporate learnings from other BD2-selective series, optimize the vector for the amide region, and explore the ZA cleft, leading to the identification of potent, selective, and bioavailable compounds 28 (GSK452), 39 (GSK737), and 36 (GSK217).

GSK973 Is an Inhibitor of the Second Bromodomains (BD2s) of the Bromodomain and Extra-Terminal (BET) Family

Pan-BET inhibitors have shown profound efficacy in a number of in vivo preclinical models and have entered the clinic in oncology trials where adverse events have been reported. These inhibitors interact equipotently with the eight bromodomains of the BET family of proteins. To better understand the contribution of each domain to their efficacy and to improve from their safety profile, selective inhibitors are required. This Letter discloses the profile of GSK973, a highly selective inhibitor of the second bromodomains of the BET proteins that has undergone extensive preclinical in vitro and in vivo characterization.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.